What if you could know before enrolling a single patient which ones will actually respond to treatment?

Pilgrim Jackson, CEO of Yatiri Bio, is using proteomics to predict treatment response in AML and ovarian cancer with 100% accuracy so far—potentially cutting Phase 2 trials from 100 patients to just 40.

🎙️ Full episode drops December 18

In the complete interview, we dive into:

• Proteomic signatures that differentiate responders from non-responders

• De-risking clinical trials and addressing patient heterogeneity

• Regulatory strategy for biomarker-driven trials

• The future of precision oncology

Subscribe so you don't miss it.

#SneakPeek #ClinicalTrials #PrecisionMedicine #Proteomics